1

Relatlimab: A Comprehensive Analysis into BMS-986016 and its Prospects

relatlimab162063
Relatlimab, formerly known as BMS-986016, represents a novel therapeutic approach in oncology, functioning as a specific LAG-3 antagonist. Its working principle centers around neutralizing the LAG-3 system, effectively https://www.targetmol.com/compound/relatlimab
Report this page

Comments

    HTML is allowed

Who Upvoted this Story